Mindmed announces initiation of phase 1 clinical trial of intravenous dmt

New york, july 28, 2021 /prnewswire/ -- mindmed (nasdaq: mnmd) (neo: mmed) (de: mmq), a leading biotech company developing psychedelic-inspired therapies, is pleased to announce the start of a phase 1 clinical trial to assess the safety, pharmacokinetics and pharmacodynamics of dmt, a naturally occurring psychedelic substance and an active ingredient in ayahuasca. the outcome of this phase 1 clinical trial is expected to facilitate potential future phase 2 clinical trials of dmt in patients.
MNMD Ratings Summary
MNMD Quant Ranking